Individuals with medical contact for traumatic brain injury (TBI) have increased risk of suicide, according to a study published in the Aug. 14 issue of the Journal of the American Medical Association.
NeuroRx has been granted Fast Track status by the U.S. Food and Drug Administration (FDA) for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone).
The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.